Department of Pharmaceutical and Pharmacological Science, Padova, 35131, Italy.
Sci Rep. 2019 Feb 4;9(1):1210. doi: 10.1038/s41598-018-37968-8.
EGFR is an oncogene that encodes for a trans-membrane tyrosine kinase receptor. Its mis-regulation is associated to several human cancers that, consistently, can be treated by selective tyrosine kinase inhibitors. The proximal promoter of EGFR contains a G-rich domain located at 272 bases upstream the transcription start site. We previously proved it folds into two main interchanging G-quadruplex structures, one of parallel and one of hybrid topology. Here we present the first evidences supporting the ability of the complementary C-rich strand (EGFR-272_C) to assume an intramolecular i-Motif (iM) structure that, according to the experimental conditions (pH, presence of co-solvent and salts), can coexist with a different arrangement we referred to as a hairpin. The herein identified iM efficiently competes with the canonical pairing of the two complementary strands, indicating it as a potential novel target for anticancer therapies. A preliminary screening for potential binders identified some phenanthroline derivatives as able to target EGFR-272_C at multiple binding sites when it is folded into an iM.
表皮生长因子受体(EGFR)是一种编码跨膜酪氨酸激酶受体的致癌基因。其失调与几种人类癌症有关,而这些癌症可以通过选择性酪氨酸激酶抑制剂进行治疗。EGFR 的近端启动子包含一个位于转录起始位点上游 272 个碱基的富含 G 的区域。我们之前已经证明它可以折叠成两种主要的相互交换的 G-四链体结构,一种是平行的,另一种是混合拓扑结构。在这里,我们首次提供了支持互补的 C 丰富链(EGFR-272_C)形成分子内 i-Motif(iM)结构的能力的证据,根据实验条件(pH 值、共溶剂和盐的存在),该结构可以与我们称为发夹的不同排列方式共存。在此鉴定的 iM 有效地与两条互补链的典型配对竞争,表明它可能成为癌症治疗的新靶点。初步筛选潜在配体表明,一些菲咯啉衍生物能够在 EGFR-272_C 折叠成 iM 时在多个结合位点靶向 EGFR-272_C。